Bayer wins EU approval for Lynkuet, expanding its pharma portfolio with a hormone-free treatment for moderate to severe ...
Everyday Health on MSN
Diagnosed With ATTR-CM: What Should I Do Now?
After a diagnosis of the heart disease transthyretin cardiac amyloidosis (ATTR-CM), starting treatment and talking to your ...
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), a leader in regenerative medicine, will attend the Innovations in Wound Care ...
The study highlights alarmingly high levels of antibiotic-resistant bacteria in participants from India, underscoring the ...
US FDA approves Henlius and Organon’s Poherdy, the first Perjeta biosimilar: Shanghai Tuesday, November 18, 2025, 16:00 Hrs [IST] Shanghai Henlius Biotech, Inc., a global health ...
Several observations from preclinical and short-term clinical studies support a role for sildenafil in the treatment of heart failure patients. The following discussion briefly considers each of these ...
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pert ...
TONMYA was approved by the FDA on August 15, 2025.
TONMYA is now available by prescription and available for pharmacy ordering nationwideTONMYA is the first FDA-approved treatment for fibromyalgia ...
The Cardiac Biomarkers Market offers opportunities in developing high-sensitivity assays, point-of-care solutions for decentralized care, and AI-supported diagnostics. Growth is driven by rising ...
Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD ...
Pertuzumab-dpzb is the first interchangeable biosimilar to pertuzumab, enhancing treatment accessibility for HER2-positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback